BioPharma Updates, May 26th, 2025.
SciLeads’ BioPharma is updated daily, giving our clients the most current insights on biopharma organizations including Funding, Initial Public Offering, Mergers & Acquisitions, Partnerships, and more. This week’s updates are below with links to the organizations in the platform. If you don’t have BioPharma yet, start your free trial today.
Download this update:
View BioPharma updates as a PDF.
View BioPharma updates in an Excel (.XLS) format.
Funding
- CellCentric (Cambridge, United Kingdom) raised $120M in Series C funding to advance inobrodib, an oral p300/CBP inhibitor, for the treatment of multiple myeloma.
- Juvenescence (Ramsey, Isle of Man) raised $76M in Series B-1 funding to advance its AI-enabled therapeutics pipeline and deliver key clinical readouts for age-related diseases.
- ReproNovo (Lausanne, Switzerland) raised $65M in Series A funding to advance its Phase 2 pipeline targeting infertility and adenomyosis in reproductive medicine and women’s health.
- FORE Biotherapeutics (PA, USA) raised $38M in Series D-2 funding to advance Phase 2 trials of plixorafenib, a BRAF inhibitor for CNS tumors and other BRAF-driven cancers.
- PHASE Scientific (Hong Kong) raised $34M in Series A funding to advance urine-based diagnostic technology for early disease detection across cancers, women’s health, and infectious diseases.
- Emtora Biosciences (TX, USA) received a $3M Cancer Prevention & Research Institute of Texas grant to support its Phase 3 trial of eRapa for familial adenomatous polyposis.
- MantaBio (MA, USA) raised $2.5M in seed funding to accelerate development of its automated platform for microbial contamination detection in biologics manufacturing.
- Life Molecular Imaging (Berlin, Germany) received a $2.16M Alzheimer’s Drug Discovery Foundation grant to advance development of [18F]F-DED PET imaging for investigating neuroinflammation in Alzheimer’s disease.
- RevolKa Ltd. (Sendai, Japan) raised $1.4M in Series A extension funding to advance AI-driven protein engineering for drug discovery in rare diseases.
- Entos Pharmaceuticals (Edmonton, Canada) received a $1M CureDuchenne Ventures grant to develop a muscle-targeting gene therapy for Duchenne muscular dystrophy using its Fusogenix PLV delivery platform.
- Senti Biosciences (CA, USA) received a $1M California Institute of Regenerative Medicine grant to advance clinical development of SENTI-202, a Logic Gated CAR-NK cell therapy for hematologic malignancies.
- ME Therapeutics (Vancouver, Canada) received $140K in funding to advance development of its mRNA therapeutic program targeting myeloid cell biology for cancer and inflammatory disease.
- Eascra Biotech (MA, USA) received a $100K MassVentures SBIR Targeted Technologies (START) grant to support development of its Janus Base Nanoparticles (JBNps), a non-lipid nanoparticle drug delivery platform.
Emerging
- Massalia Therapeutics (Marseille, France) raised an undisclosed amount in seed funding to advance an IND-ready first-in-class therapeutic targeting cancer and fibrosis.
- Apreo Health (CA, USA) emerged from stealth to pioneer a non-destructive implant, the BREATHE Airway Scaffold, to relieve lung pressure in severe emphysema patients without harming healthy tissue.
- Mubadala Bio (Abu Dhabi, United Arab Emirates) launched to boost the UAE’s pharmaceutical manufacturing capacity and global presence in life sciences by producing a wide range of medicines and supporting national drug security and innovation.
- Elvinix (DE, USA) is currently operating in stealth to develop a functional cure for Type 1 Diabetes through innovative biotech solutions.
- Apoha (London, United Kingdom) is currently operating in stealth to develop Sensory Intelligence that seamlessly integrates machines into physical reality.
- epiome.ai (London, United Kingdom) is currently operating in stealth mode to develop advanced AI-driven precision diagnostics aimed at transforming the early detection and personalized treatment of neurological diseases.
Post IPO Equity
- Gyre Therapeutics (CA, USA) raised $20M through an underwritten public offering to advance its Phase 2 clinical trial of F351 for MASH-associated liver fibrosis, support R&D, manufacturing, working capital, and general corporate purposes.
- NanoVibronix (NY, USA) raised $10M through an underwritten public offering to redeem debt and support general corporate purposes.
- Poolbeg Pharma (London, United Kingdom) raised $6M through an oversubscribed placing and direct subscription of new ordinary shares to advance its clinical trials, extend its financial runway into 2027, and support working capital.
- CEL-SCI (VA, USA) raised $5M through an underwritten public offering to fund the continued development of Multikine, general corporate purposes, and working capital.
- Mainz Biomed (Mainz, Germany) raised $4M through a follow-on offering to support its operations and ongoing cancer diagnostics programs.
- Protagenic Therapeutics Inc. (NY, USA) raised $3.1M through warrant exercises to fund working capital and advance peptide-based drug candidates for stress-related and central nervous system disorders.
- Telomir Pharmaceuticals (FL, USA) raised $3M through a direct equity investment from The Bayshore Trust, its largest shareholder, to strengthen its balance sheet and fund Telomir-1’s upcoming IND submission for a rare disease indication.
- XORTX Therapeutics (Calgary, Canada) raised $3M through a private placement to advance its gout programs and support working capital and general corporate purposes.
- AB Science (Paris, France) raised ~$2M through a private placement to finance ongoing activities, primarily clinical development of its AB8939 program.
- PreveCeutical Medical Inc. (Vancouver, Canada) raised $748K through a non-brokered private placement to pay outstanding payables, operating expenses, and general working capital.
- NorthX Biologics (Matfors, Sweden) raised an undisclosed amount through a growth equity investment to accelerate expansion, enhance facilities, broaden service lines, and extend its U.S. commercial reach.
- Outlook Therapeutics, Inc. (NJ, USA) raised an undisclosed amount through an underwritten public offering of common stock and warrants to support working capital and general corporate purposes.
Post IPO Debt
- Teva Pharmaceuticals (Tel Aviv, Israel) raised $2.3B through an upsized offering of senior notes to fund tender offers for existing debt, pay related fees and expenses, and for general debt repayment purposes.
- Idorsia Pharmaceuticals Ltd (Allschwil, Switzerland) raised ~$165M through a new money facility backed by bondholders to extend its cash runway to mid-2026 and support ongoing operations amid convertible debt restructuring.
- Cizzle Biotechnology Plc (London, United Kingdom) raised $190K through a convertible loan note subscribed by an existing investor to support the roll-out of its early cancer test in the UK and Europe and advance its growth strategy.
Mergers and Acquisitions
- Sanofi (Paris, France) to acquire Vigil Neuroscience (MA, USA) for up to $670M, adding the oral TREM2 agonist VG-3927 for Alzheimer’s disease to its neurology pipeline.
- Regeneron Pharmaceuticals, Inc. (NY, USA) has agreed to acquire 23andMe (CA, USA) for $256M to bolster its drug discovery capabilities using 23andMe’s extensive genetic data. The acquisition supports Regeneron’s goal of improving human health through genetics-based research while maintaining 23andMe’s consumer genetics business.
- Waters Corporation (MA, USA) has acquired Halo Labs (OR, USA), a developer of specialized imaging technologies for particle analysis in cell, protein, and gene therapies, to expand Waters’ capabilities in analytical and bioprocessing testing for large molecule therapies.
- Altos Labs (CA, USA) acquired Dorian Therapeutics (CA, USA), an anti-aging startup, to expand its portfolio of longevity-focused therapeutics.
Partnerships
- Pfizer (NY, USA) and 3SBio Inc. (Shanghai, China) announced a ~$6.05B exclusive global (ex-China) licensing agreement for SSGJ-707, a bispecific antibody for cancer.
- Orionis Biosciences (MA, USA) and Genentech (CA, USA) announced a ~$2.1B multi-year collaboration for the discovery of small-molecule monovalent glues using Orionis’s Allo-Glue™ platform.
- VantAI (NY, USA) and Blueprint Medicines (MA, USA) expanded their collaboration to include additional drug programs targeting previously undruggable diseases, with VantAI eligible for up to $1.67 billion in milestone payments and royalties.
- CRISPR Therapeutics (MA, USA) and Sirius Therapeutics (CA, USA) announced a $95M partnership to co-develop and co-commercialize SRSD107, a next-generation Factor XI siRNA therapy for thromboembolic disorders, with options for up to two additional siRNA programs.
- Murdoch Children’s Research Institute (Melbourne, Australia) and Retro Biosciences (CA, USA) announced a $35M research and commercial licensing agreement to advance MCRI’s blood stem cell technology for developing new personalized therapies for blood disorders.
- GENFIT (Loos, France) received a $28.8M milestone payment from Ipsen (France) after Iqirvo (elafibranor) secured pricing and reimbursement approval for PBC in Italy, under their licensing and collaboration agreement.
- Lamassu Biotech (NC, USA) and The Ohio State University (OH, USA) announced a research collaboration to advance RABI-767, a novel therapeutic for acute pancreatitis in dogs and humans.
- Synoligo Biotechnologies (NC, USA) and Lumiphore (CA, USA) announced a partnership to develop next-generation lanthanide-based oligonucleotide probes for diagnostic tests and life science research.
- Porton Advanced (NJ, USA) and Hualong Biological (China) announced a partnership for Porton Advanced to provide end-to-end CDMO services supporting the development and clinical advancement of Hualong’s Multi-Activated T Cell (MATC) therapy for solid tumors.
- Rani Therapeutics (CA, USA) and Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan) announced a research agreement to evaluate the RaniPill® oral delivery platform with two molecules for undisclosed targets.
- Skye Bioscience Inc. (CA, USA) and Arecor Therapeutics (Cambridge, United Kingdom) announced a formulation development collaboration to create a higher concentration version of nimacimab, Skye’s CB1 inhibitor for obesity, using Arecor’s Arestat™ technology.
- Maipl Therapeutics (NY, USA) and Endosure (MD, USA) announced a strategic partnership to accelerate clinical development of MA-4604, a first-in-class non-hormonal endometriosis therapy, by incorporating the ENDOSURE TEST—a rapid, non-invasive diagnostic—for improved patient identification and trial efficiency.
- Mirai Bio (MD, USA) and Thermo Fisher Scientific (MA, USA) announced a strategic partnership, including a direct investment, to accelerate the co-development and manufacturing of novel nucleic acid therapeutics, leveraging Mirai’s machine intelligence-driven platform and Thermo Fisher’s cGMP services and global manufacturing capabilities.
- Tempus AI (IL, USA) and Verastem Oncology (MA, USA) announced a collaboration to develop a companion diagnostic (CDx) test for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC), leveraging Tempus’ xT CDx assay to support ongoing and future clinical trials.
- Viz.ai (CA, USA), Sanofi (Paris, France), and Regeneron (NY, USA) announced a multi-year partnership to deploy and assess an AI-powered workflow for improved detection and management of high-risk COPD patients.
- Antengene (Shanghai, China) and MSD (NJ, USA) announced a global clinical collaboration to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.
- Evofem Biosciences (CA, USA) and Pharma 1 Drug Store LLC (Dubai, United Arab Emirates) announced a license and supply agreement granting Pharma 1 exclusive Middle East rights to SOLOSEC®, with Evofem receiving upfront, regulatory, and sales-based milestone payments and supplying the product at cost-plus.
- Neurogen Biomarking (IL, USA) and Aranscia (TX, USA) announced a partnership to utilize Aranscia’s lab and software solutions to support Neurogen’s blood-based biomarker platform for early detection of mild cognitive impairment and Alzheimer’s disease.
- RamSoft (Toronto, Canada) and Therapixel (Nice, France) announced a commercial partnership to integrate Therapixel’s AI-powered MammoScreen® breast imaging software into RamSoft’s PowerServer™ and OmegaAI® platforms, enhancing cancer detection and radiologist workflow within cloud-based imaging systems.
- Kaida BioPharma (FL, USA) and Northway Biotech (Vilnius, Lithuania) announced a manufacturing agreement for KAD101, a novel prolactin receptor antagonist, to advance process development and cGMP production for an upcoming Phase 1 trial in platinum-resistant ovarian cancer.
- Aptar Digital Health (NY, USA) and AstraZeneca (Cambridge, United Kingdom) announced a licensing agreement to develop and commercialize AI-driven algorithms for early detection of cardiovascular, renal, and metabolic conditions such as chronic kidney disease during eye examinations.
- Twist Bioscience (CA, USA) and Element Biosciences (CA, USA) announced an expanded collaboration to develop exclusive library preparation and target enrichment workflows for Element’s AVITI systems and Trinity flowcells, streamlining NGS applications for research and clinical markets.
- Roche (Switzerland) and Broad Clinical Labs (MA, USA) announced a strategic collaboration to develop and pilot clinical and research applications using Roche’s next-generation SBX sequencing technology, with an initial focus on trio-based whole genome sequencing for critically ill newborns and their parents.
Initial Public Offering (IPO)
- Hinge Health (CA, USA) raised an undisclosed amount through an initial public offering (IPO) to satisfy tax obligations related to equity compensation and support corporate activities
Registered Direct Offering (RDO)
- Jaguar Health (CA, USA) raised $1.5M through a registered direct offering to support general corporate purposes, including growth capital, working capital, operating expenses, debt repayment, and capital expenditures.
Closures and Layoffs
- Prime Medicine, Inc. (MA, USA) has announced they will be laying off 25% of their employees
- Schrödinger (NY, USA) has announced they will be laying off 60 employees which is approximately 7% of their workforce.
- Eikon Therapeutics (CA, USA) has announced a second round of layoffs in 19 months due to financial challenges stemming from changes in external circumstances.
Is there anything else you’d love to see here or have added to the platform? Please don’t hesitate to contact us with your feedback.